Cordis Company Profile

Background

Overview: Cordis is a global leader in the development and manufacturing of interventional cardiovascular technologies. With a legacy spanning over 60 years, the company has been at the forefront of pioneering medical devices, including the first guidewires and drug-eluting stents. Cordis operates in more than 70 countries, delivering innovative solutions to address coronary and peripheral vascular diseases.

Mission and Vision: Cordis is dedicated to transforming cardiovascular care through innovation, clinical expertise, and customer-centric services. The company's mission is to develop differentiated solutions that improve patient vitality and help lower the cost of care.

Industry Significance: As a prominent player in the medical device industry, Cordis has significantly contributed to advancements in interventional cardiology and endovascular procedures. Its products are integral to diagnosing and treating circulatory system disorders, impacting millions of lives worldwide.

Key Strategic Focus

Core Objectives:

Innovation: Continuously develop and introduce breakthrough technologies in cardiovascular care.

Global Expansion: Strengthen presence in existing markets and explore new opportunities worldwide.

Customer-Centric Approach: Enhance clinical outcomes and provide impactful educational platforms for healthcare professionals.

Areas of Specialization:

Vascular Closure Devices: Products like the MYNX CONTROL™ VENOUS Vascular Closure Device designed for rapid hemostasis.

Radial and Pedal Access: Innovations such as the Radianz Radial Peripheral System™ optimized for radial access and treatment.

Interventional Tools: Comprehensive portfolios including guidewires, catheters, and stents for various interventional procedures.

Key Technologies Utilized:

Drug-Eluting Balloons: Acquisition of MedAlliance and its SELUTION SLR™ Drug-Eluting Balloon technology.

Radial Access Systems: Development of systems facilitating minimally invasive procedures with improved patient outcomes.

Primary Markets Targeted:

North America

Europe, Middle East, and Africa (EMEA)

Asia-Pacific

Latin America

Financials and Funding

Funding History:

2015: Acquired by Cardinal Health from Johnson & Johnson for $1.944 billion.

2021: Sold to private equity firm Hellman & Friedman for $1 billion.

Notable Investors:

Hellman & Friedman, LLC: A global private equity firm focusing on large-scale equity investments in high-quality growth businesses.

KKR: A private equity firm investing in private equity, credit, and real assets.

Utilization of Capital:

Innovation Acceleration: Establishment of Cordis-X, an independent innovation accelerator.

Strategic Acquisitions: Acquisition of MedAlliance to enhance the product portfolio.

Global Expansion: Strengthening operations and market presence across various regions.

Pipeline Development

Key Pipeline Candidates:

SELUTION SLR™ Drug-Eluting Balloon: A novel sirolimus-eluting balloon designed for controlled and sustained drug release.

Stages of Development:

Clinical Trials: Ongoing studies to evaluate the efficacy and safety of the SELUTION SLR™ in treating peripheral artery disease.

Target Conditions:

Peripheral Artery Disease (PAD)

Coronary Artery Disease (CAD)

Anticipated Milestones:

Regulatory Approvals: Pursuit of FDA and other global regulatory clearances.

Commercial Launches: Introduction of new products in key markets upon approval.

Technological Platform and Innovation

Proprietary Technologies:

SELUTION SLR™ Technology: Utilizes proprietary sirolimus release technology for sustained drug delivery.

Significant Scientific Methods:

Drug-Eluting Mechanisms: Development of devices that provide controlled drug release to target tissues.

Minimally Invasive Techniques: Advancements in devices facilitating less invasive cardiovascular procedures.

Leadership Team

Scott Drake, Chief Executive Officer: Over 30 years in medical devices, former CEO of Spectranetics Corporation.

Duke Rohlen, Executive Chairman (Cordis-X): CEO and Managing Director of Ajax Health, with a history of building and selling medical device companies.

Christopher Scully, Chief Financial Officer: Former EVP and CFO for PPD, with extensive experience in financial leadership.

Nancy Pounder, Chief Human Resources Officer: 25 years in global HR, previously Global VP at Zimmer Biomet.

Dr. George Adams, Chief Medical Officer: Globally recognized for expertise in peripheral vascular disease and coronary artery disease.

Dominique Boulet, President, International: Over 25 years in medical devices, former President and Chairman of J&J’s medical business in Germany.

Matthew Muscari, President, Americas: 20 years in medical device commercial leadership, former leader at Cardiovascular Systems, Inc.

Chris Bingham, Vice President, Global Marketing & Strategy: Over 20 years in marketing and strategy, former leader at Sonova’s cochlear implant business.

Leadership Changes

2021: Scott Drake appointed as CEO, bringing extensive experience in medical device leadership.

2021: Duke Rohlen appointed as Executive Chairman of Cordis-X, focusing on innovation acceleration.

Competitor Profile

Market Insights and Dynamics:

Market Size: The global interventional cardiology devices market is projected to reach significant growth, driven by increasing prevalence of cardiovascular diseases.

Growth Potential: Advancements in minimally invasive procedures and technological innovations are key growth drivers.

Industry Trends: Shift towards radial access procedures, development of bioresorbable stents, and integration of AI in diagnostics.

Competitor Analysis:

Medtronic: Offers a comprehensive portfolio in cardiac and vascular therapies.

Abbott Laboratories: Known for its coronary stents and structural heart products.

Boston Scientific: Provides a wide range of interventional cardiology devices.

Stryker: Engages in the development of medical devices, including those for cardiovascular applications.

Strategic Collaborations and Partnerships

Cordis-X: An independent innovation accelerator in partnership with Ajax Health, focusing on rapid development of new technologies.

MedAlliance Acquisition: Enhances Cordis's portfolio with the SELUTION SLR™ Drug-Eluting Balloon technology.

Operational Insights

Strategic Considerations:

Competitive Positioning: Leveraging a legacy of innovation to differentiate in a competitive market.

Market Position: Strong global presence with operations in over 70 countries.

Competitive Advantages:

Innovative Product Portfolio: Continuous development of cutting-edge technologies.

Global Distribution Network: Extensive reach facilitating market penetration.

Customer-Centric Approach: Focus on enhancing clinical outcomes and providing educational platforms.

Strategic Opportunities and Future Directions

Strategic Roadmap:

Product Innovation: Accelerate development of next-generation cardiovascular devices.

Market Expansion: Explore emerging markets and strengthen presence in existing ones.

Technological Integration: Incorporate AI and data analytics to enhance product offerings.

Opportunities for Expansion:

Digital Health Solutions: Develop remote monitoring and telehealth capabilities.

Personalized Medicine: Create tailored therapies based on patient-specific data.

Positioning for Future Objectives:

Leveraging Legacy: Utilize decades of expertise to drive future innovations.

Strategic Partnerships: Collaborate with technology firms to enhance product capabilities.

Sustainability Initiatives: Implement eco-friendly practices in manufacturing and operations.

Contact Information

Website: cordis.com

Headquarters: Miami Lakes, Florida, USA

For more information, visit the official Cordis website.

cordis